ENLIVEX LTD (ENLV) Fundamental Analysis & Valuation

NASDAQ:ENLV • IL0011319527

Current stock price

0.8885 USD
-0.02 (-2.01%)
Last:

This ENLV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ENLV Profitability Analysis

1.1 Basic Checks

  • ENLV had negative earnings in the past year.
  • In the past year ENLV has reported a negative cash flow from operations.
  • In the past 5 years ENLV always reported negative net income.
  • ENLV had a negative operating cash flow in each of the past 5 years.
ENLV Yearly Net Income VS EBIT VS OCF VS FCFENLV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • ENLV's Return On Assets of -60.66% is on the low side compared to the rest of the industry. ENLV is outperformed by 60.27% of its industry peers.
  • ENLV has a Return On Equity (-72.66%) which is in line with its industry peers.
Industry RankSector Rank
ROA -60.66%
ROE -72.66%
ROIC N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ENLV Yearly ROA, ROE, ROICENLV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENLV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENLV Yearly Profit, Operating, Gross MarginsENLV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

8

2. ENLV Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENLV Yearly Shares OutstandingENLV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENLV Yearly Total Debt VS Total AssetsENLV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 26.99 indicates that ENLV is not in any danger for bankruptcy at the moment.
  • ENLV has a better Altman-Z score (26.99) than 90.70% of its industry peers.
  • There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.99
ROIC/WACCN/A
WACCN/A
ENLV Yearly LT Debt VS Equity VS FCFENLV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 6.43 indicates that ENLV has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.43, ENLV is doing good in the industry, outperforming 64.53% of the companies in the same industry.
  • ENLV has a Quick Ratio of 6.43. This indicates that ENLV is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ENLV (6.43) is better than 65.12% of its industry peers.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 6.43
ENLV Yearly Current Assets VS Current LiabilitesENLV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

1

3. ENLV Growth Analysis

3.1 Past

  • The earnings per share for ENLV have decreased strongly by -1019.18% in the last year.
EPS 1Y (TTM)-1019.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3313.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ENLV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.53% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96%
EPS Next 2Y37.94%
EPS Next 3Y23.48%
EPS Next 5Y18.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENLV Yearly Revenue VS EstimatesENLV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ENLV Yearly EPS VS EstimatesENLV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 -20 -30 -40

1

4. ENLV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENLV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENLV Price Earnings VS Forward Price EarningsENLV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENLV Per share dataENLV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ENLV's earnings are expected to grow with 23.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.94%
EPS Next 3Y23.48%

0

5. ENLV Dividend Analysis

5.1 Amount

  • ENLV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ENLV Fundamentals: All Metrics, Ratios and Statistics

ENLIVEX LTD

NASDAQ:ENLV (4/24/2026, 4:25:46 PM)

0.8885

-0.02 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-25
Inst Owners0.83%
Inst Owner Change0%
Ins Owners0.46%
Ins Owner Change0%
Market Cap210.91M
Revenue(TTM)N/A
Net Income(TTM)-12.70M
Analysts80
Price Target20.4 (2196%)
Short Float %0.23%
Short Ratio0.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)26.47%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)10.02%
Min EPS beat(4)-45.48%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)2.19%
EPS beat(12)8
Avg EPS beat(12)3.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)53.85%
PT rev (3m)53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)23.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.07
P/tB 12.07
EV/EBITDA N/A
EPS(TTM)-8.17
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -60.66%
ROE -72.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 6.43
Altman-Z 26.99
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)362.73%
Cap/Depr(5y)347.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1019.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3313.04%
EPS Next Y96%
EPS Next 2Y37.94%
EPS Next 3Y23.48%
EPS Next 5Y18.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.5%
OCF growth 3YN/A
OCF growth 5YN/A

ENLIVEX LTD / ENLV Fundamental Analysis FAQ

What is the fundamental rating for ENLV stock?

ChartMill assigns a fundamental rating of 3 / 10 to ENLV.


What is the valuation status for ENLV stock?

ChartMill assigns a valuation rating of 1 / 10 to ENLIVEX LTD (ENLV). This can be considered as Overvalued.


Can you provide the profitability details for ENLIVEX LTD?

ENLIVEX LTD (ENLV) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ENLIVEX LTD?

The Earnings per Share (EPS) of ENLIVEX LTD (ENLV) is expected to grow by 96% in the next year.